Suma10 mg/spray

Suma is a triptan medicine used for the acute (abortive) treatment of certain headache disorders. It does not prevent attacks and is not for daily/prophylactic use.

Suma is not indicated for prevention (prophylaxis) of migraine, for hemiplegic or basilar migraine, or for tension-type or other non-migraine headaches.

Sumatriptan (as sumatriptan succinate, or as sumatriptan base in nasal formulations) is available in several strengths and dosage forms:

• Oral tablets: 25 mg, 50 mg, and 100 mg
• Subcutaneous injection: 4 mg/0.5 mL and 6 mg/0.5 mL (prefilled syringe/auto-injector)
• Nasal spray: 5 mg, 10 mg, and 20 mg per single spray

Available strengths and dosage forms may vary by manufacturer and by market.

Suma is a selective serotonin (5-HT1B/1D) receptor agonist belonging to the triptan class of medicines, used for the acute relief of migraine and cluster headache attacks. It works by narrowing dilated blood vessels around the brain and reducing the release of substances that trigger migraine pain and inflammation.

Suma is intended to treat an attack that has already started; it is taken (or administered) as early as possible after the onset of headache and is not used to prevent attacks from occurring.

Suma belongs to the triptan class of drugs — selective serotonin 5-HT1B/1D receptor agonists, classified therapeutically as anti-migraine agents.

Mechanism of Action

Sumatriptan is a selective agonist at 5-HT1B and 5-HT1D serotonin receptors. Activation of 5-HT1B receptors on cranial blood vessels produces vasoconstriction of dilated, dural blood vessels believed to be distended during a migraine attack. Activation of 5-HT1D receptors on trigeminal nerve terminals inhibits the release of pro-inflammatory and vasoactive neuropeptides (such as calcitonin gene-related peptide), reducing neurogenic inflammation and blocking pain transmission along the trigeminovascular pathway.

Pharmacokinetics

• Absorption: Oral bioavailability is low (about 14%) due to extensive first-pass metabolism and incomplete absorption; peak plasma concentration is reached in about 2–2.5 hours. Subcutaneous injection has much higher bioavailability (~96%) with a rapid peak (~10–15 minutes). Nasal spray has intermediate bioavailability and onset.
• Distribution: Plasma protein binding is low (14–21%).
• Metabolism: Predominantly metabolized by monoamine oxidase A (MAO-A) to an inactive indole acetic acid metabolite.
• Elimination: Elimination half-life is approximately 2.5 hours; metabolites are excreted mainly in urine.

• Tablets: Swallow whole with water; may be taken with or without food.
• Subcutaneous injection: Administer using the prefilled auto-injector/syringe exactly as instructed by a healthcare provider, into the thigh or outer upper arm; do not inject intravenously.
• Nasal spray: Administer one full spray into a single nostril; do not shake; prime according to the package instructions if it is the first use of that device; blow the nose gently before use if needed.
• Use Suma as soon as possible after migraine or cluster headache symptoms begin.

Serotonergic drugs (SSRIs, SNRIs, and other serotonergic agents): Concomitant use with Suma carries a risk of serotonin syndrome (agitation, hallucinations, rapid heart rate, tremor, muscle rigidity, incoordination, diarrhea, in rare cases life-threatening). Use with caution and monitor closely if combined.

Ergot-containing medicines, other triptans, and MAO inhibitors: Do not combine — these are absolute contraindications with defined time restrictions; see Contraindications.

Other 5-HT1 agonists: Additive vasospastic effects are possible; avoid concurrent use.

No clinically significant interaction has been established with propranolol, or with common CYP450 enzyme pathways, as Suma is metabolized predominantly by monoamine oxidase A rather than cytochrome P450 enzymes.

Common side effects of Suma include:

• Tingling, numbness, or pins-and-needles sensation (paresthesia)
• Flushing or feeling of warmth
• Mild sensation of pain, pressure, or tightness in the chest, neck, jaw, or throat — usually transient and not of cardiac origin, but should be evaluated promptly if severe, persistent, or occurring with risk factors for heart disease (see Precautions and Warnings)
• Dizziness or drowsiness
• Injection site reactions (with subcutaneous use) or nasal discomfort, throat irritation, and altered taste (with nasal spray)
• Fatigue and mild nausea

Rare but serious effects — including cardiac ischemia, stroke, serotonin syndrome, seizures, and anaphylaxis — are discussed under Precautions and Warnings.

Pregnancy: Suma should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Data from pregnancy exposure registries have generally been reassuring for this class, but formal safety in human pregnancy has not been established, and a physician should always be consulted before use.

Breastfeeding: Suma passes into breast milk in small amounts. Because effects on a nursing infant are not fully established, caution is advised; some guidance suggests avoiding breastfeeding for about 12 hours after a dose (expressing and discarding milk during this period) to minimize infant exposure. Consult a physician before use while breastfeeding.

• Cardiac risk evaluation: Suma should not be given to patients with unrecognized coronary artery disease without prior cardiovascular evaluation, particularly those with risk factors (e.g. diabetes, smoking, hypertension, high cholesterol, obesity, strong family history, postmenopausal women, men over 40). Serious cardiac events (myocardial ischemia/infarction, arrhythmia) have occurred rarely, even in patients without known cardiac disease.
• Cerebrovascular and peripheral vasospastic events: Stroke, hemorrhage, and other cerebrovascular events, as well as peripheral vasospastic reactions (including ischemic colitis and Raynaud's-type symptoms), have been reported rarely.
• Serotonin syndrome: Risk increases when combined with other serotonergic drugs (see Interactions).
• Medication-overuse headache: Frequent use (more than about 10 days per month) can lead to worsening headache; limit frequency of use per medical advice.
• Seizures: Use with caution in patients with a history of seizure disorder or conditions that lower seizure threshold.
• Hypersensitivity/anaphylaxis: Discontinue immediately if signs of a serious allergic reaction occur.
• Hepatic impairment: Use the lowest dose in mild-to-moderate impairment; avoid in severe impairment (see Contraindications).

Reported effects of Suma overdose include seizures, tremor, cyanosis, weakness, ataxia (incoordination), significant changes in blood pressure, and loss of consciousness, particularly with injectable formulations.

There is no specific antidote. If an overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center. Continued observation, including cardiac (ECG) monitoring for at least 10 hours, and supportive/symptomatic treatment should be provided by medical professionals; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze injectable or nasal spray formulations. Keep out of reach of children.

• Renal impairment: No specific dose adjustment is well established; use with caution, as Suma and its metabolites are partly renally eliminated.
• Hepatic impairment: Use the lowest available dose in mild-to-moderate impairment; contraindicated in severe hepatic impairment (see Contraindications).
• Elderly: Use with caution, as older adults are more likely to have undiagnosed coronary artery disease; cardiovascular risk should be assessed before use.
• Pediatric patients: See Pediatric Uses.

Suma is intended only for the acute (as-needed) treatment of an individual migraine or cluster headache attack, not for daily or preventive use. A dose (and, if needed, one repeat dose per the interval and maximum described in Dosage and Administration) is used for each attack. Use on more than about 10 days per month should be avoided, as this can itself cause medication-overuse headache (see Precautions and Warnings).

Triptans (selective serotonin 5-HT1B/1D receptor agonists); anti-migraine preparations (ATC class N02CC01). Sumatriptan is not an antibiotic or antimicrobial.

Sumatriptan selectively stimulates 5-HT1B and 5-HT1D serotonin receptors, causing constriction of dilated cranial (dural) blood vessels and inhibiting the release of pro-inflammatory neuropeptides from trigeminal nerve endings. This dual action interrupts the vascular dilation and neurogenic inflammation that underlie migraine and cluster headache pain.

C

Oral tablets and subcutaneous injection: Safety and efficacy of Suma have not been established in patients under 18 years of age; these formulations are not recommended in children or adolescents.

Nasal spray: Approved for the acute treatment of migraine in adolescents aged 12–17 years, as a single weight-based dose (10 mg or 20 mg) in one nostril. The safety and effectiveness of a second dose in this age group have not been established. Suma is not approved for migraine prevention or for cluster headache in any pediatric patient, and is not studied in children under 12 years.